浙江医药：拟向激励对象875人授予限制性股票1028.4万股

Core Viewpoint - Zhejiang Medicine announced an incentive plan involving 875 participants, granting up to 10.284 million restricted stocks, representing approximately 1.0694% of the company's total share capital of about 962 million shares [1] Group 1: Incentive Plan Details - The incentive plan will grant restricted stocks at a price of 7.3 yuan per share, with a maximum validity of 36 months from the completion of the stock registration [1] - The stocks are sourced from the company's repurchased A-shares in the secondary market, with no reserved rights set [1] Group 2: Financial Performance - For the first half of 2025, Zhejiang Medicine's revenue composition is as follows: pharmaceuticals account for 51.44%, human nutritional products for 47.06%, and other businesses for 1.51% [1] - As of the report date, Zhejiang Medicine's market capitalization stands at 13.9 billion yuan [1]